A citation-based method for searching scientific literature

Roxana Daneshjou, Eric R Gamazon, Ben Burkley, Larisa H Cavallari, Julie A Johnson, Teri E Klein, Nita Limdi, Sara Hillenmeyer, Bethany Percha, Konrad J Karczewski, Taimour Langaee, Shitalben R Patel, Carlos D Bustamante, Russ B Altman, Minoli A Perera. Blood 2014
Times Cited: 43







List of co-cited articles
249 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Minoli A Perera, Larisa H Cavallari, Nita A Limdi, Eric R Gamazon, Anuar Konkashbaev, Roxana Daneshjou, Anna Pluzhnikov, Dana C Crawford, Jelai Wang, Nianjun Liu,[...]. Lancet 2013
183
48

A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Stephen E Kimmel, Benjamin French, Scott E Kasner, Julie A Johnson, Jeffrey L Anderson, Brian F Gage, Yves D Rosenberg, Charles S Eby, Rosemary A Madigan, Robert B McBane,[...]. N Engl J Med 2013
533
44

Estimation of the warfarin dose with clinical and pharmacogenetic data.
T E Klein, R B Altman, N Eriksson, B F Gage, S E Kimmel, M-T M Lee, N A Limdi, D Page, D M Roden, M J Wagner,[...]. N Engl J Med 2009
44

A randomized trial of genotype-guided dosing of warfarin.
Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg,[...]. N Engl J Med 2013
573
34

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
B F Gage, C Eby, J A Johnson, E Deych, M J Rieder, P M Ridker, P E Milligan, G Grice, P Lenzini, A E Rettie,[...]. Clin Pharmacol Ther 2008
568
27

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Nita A Limdi, Mia Wadelius, Larisa Cavallari, Niclas Eriksson, Dana C Crawford, Ming-Ta M Lee, Chien-Hsiun Chen, Alison Motsinger-Reif, Hersh Sagreiya, Nianjun Liu,[...]. Blood 2010
269
27

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Mark J Rieder, Alexander P Reiner, Brian F Gage, Deborah A Nickerson, Charles S Eby, Howard L McLeod, David K Blough, Kenneth E Thummel, David L Veenstra, Allan E Rettie. N Engl J Med 2005
25

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren,[...]. PLoS Genet 2009
461
20

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
Gregory M Cooper, Julie A Johnson, Taimour Y Langaee, Hua Feng, Ian B Stanaway, Ute I Schwarz, Marylyn D Ritchie, C Michael Stein, Dan M Roden, Joshua D Smith,[...]. Blood 2008
319
18

CYP4F2 genetic variant alters required warfarin dose.
Michael D Caldwell, Tarif Awad, Julie A Johnson, Brian F Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y Langaee, Charles Eby,[...]. Blood 2008
389
18

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
M A Perera, E Gamazon, L H Cavallari, S R Patel, S Poindexter, R A Kittles, D Nicolae, N J Cox. Clin Pharmacol Ther 2011
85
18

Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
Larisa H Cavallari, Minoli Perera, Mia Wadelius, Panos Deloukas, Gelson Taube, Shitalben R Patel, Keston Aquino-Michaels, Marlos A G Viana, Nancy L Shapiro, Edith A Nutescu. Pharmacogenet Genomics 2012
25
32

Genetic and clinical predictors of warfarin dose requirements in African Americans.
L H Cavallari, T Y Langaee, K M Momary, N L Shapiro, E A Nutescu, W A Coty, M A G Viana, S R Patel, J A Johnson. Clin Pharmacol Ther 2010
149
16

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G D Tuddenham,[...]. Nature 2004
807
16

Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
Katarzyna Drozda, Shan Wong, Shitalben R Patel, Adam P Bress, Edith A Nutescu, Rick A Kittles, Larisa H Cavallari. Pharmacogenet Genomics 2015
57
16

Race influences warfarin dose changes associated with genetic factors.
Nita A Limdi, Todd M Brown, Qi Yan, Jonathan L Thigpen, Aditi Shendre, Nianjun Liu, Charles E Hill, Donna K Arnett, T Mark Beasley. Blood 2015
67
16

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
16

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
309
16


Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
Pei-Chieng Cha, Taisei Mushiroda, Atsushi Takahashi, Michiaki Kubo, Shiro Minami, Naoyuki Kamatani, Yusuke Nakamura. Hum Mol Genet 2010
104
13

Cytochrome p-450 polymorphisms and response to clopidogrel.
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Richard D Hockett, John T Brandt, Joseph R Walker, Elliott M Antman, William Macias, Eugene Braunwald,[...]. N Engl J Med 2009
13

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K Higashi, David L Veenstra, L Midori Kondo, Ann K Wittkowsky, Sengkeo L Srinouanprachanh, Fred M Farin, Allan E Rettie. JAMA 2002
793
13

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Nita A Limdi, Donna K Arnett, Joyce A Goldstein, T Mark Beasley, Gerald McGwin, Brian K Adler, Ronald T Acton. Pharmacogenomics 2008
120
13

Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.
H Schelleman, J Chen, Z Chen, J Christie, C W Newcomb, C M Brensinger, M Price, A S Whitehead, C Kealey, C F Thorn,[...]. Clin Pharmacol Ther 2008
99
11

A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
P J Avery, A Jorgensen, A K Hamberg, M Wadelius, M Pirmohamed, F Kamali. Clin Pharmacol Ther 2011
55
11

Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.
Y Liu, H Jeong, H Takahashi, K Drozda, S R Patel, N L Shapiro, E A Nutescu, L H Cavallari. Clin Pharmacol Ther 2012
67
11

HLA-B*5701 screening for hypersensitivity to abacavir.
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
11

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
620
11

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Jessica L Mega, Tabassome Simon, Jean-Philippe Collet, Jeffrey L Anderson, Elliott M Antman, Kevin Bliden, Christopher P Cannon, Nicolas Danchin, Betti Giusti, Paul Gurbel,[...]. JAMA 2010
782
11

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
439
11

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
D Voora, D C Koboldt, C R King, P A Lenzini, C S Eby, R Porche-Sorbet, E Deych, M Crankshaw, P E Milligan, H L McLeod,[...]. Clin Pharmacol Ther 2010
73
11

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
Giovanna D'Andrea, Rosa Lucia D'Ambrosio, Pasquale Di Perna, Massimiliano Chetta, Rosa Santacroce, Vincenzo Brancaccio, Elvira Grandone, Maurizio Margaglione. Blood 2005
543
9

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Stuart A Scott, Rame Khasawneh, Inga Peter, Ruth Kornreich, Robert J Desnick. Pharmacogenomics 2010
127
9


Pharmacogenetics of warfarin: current status and future challenges.
M Wadelius, M Pirmohamed. Pharmacogenomics J 2007
227
9

Integration of genetic, clinical, and INR data to refine warfarin dosing.
P Lenzini, M Wadelius, S Kimmel, J L Anderson, A L Jorgensen, M Pirmohamed, M D Caldwell, N Limdi, J K Burmester, M B Dowd,[...]. Clin Pharmacol Ther 2010
171
9

Genetic warfarin dosing: tables versus algorithms.
Brian S Finkelman, Brian F Gage, Julie A Johnson, Colleen M Brensinger, Stephen E Kimmel. J Am Coll Cardiol 2011
93
9

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
Elaine M Hylek, Carmella Evans-Molina, Carol Shea, Lori E Henault, Susan Regan. Circulation 2007
765
9

Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations.
M A Perera, L H Cavallari, J A Johnson. Clin Pharmacol Ther 2014
31
12

The largest prospective warfarin-treated cohort supports genetic forecasting.
Mia Wadelius, Leslie Y Chen, Jonatan D Lindh, Niclas Eriksson, Mohammed J R Ghori, Suzannah Bumpstead, Lennart Holm, Ralph McGinnis, Anders Rane, Panos Deloukas. Blood 2009
409
9

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
S Mallal, D Nolan, C Witt, G Masel, A M Martin, C Moore, D Sayer, A Castley, C Mamotte, D Maxwell,[...]. Lancet 2002
958
9

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
E Link, S Parish, J Armitage, L Bowman, S Heath, F Matsuda, I Gut, M Lathrop, R Collins. N Engl J Med 2008
9


Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.
Adam Bress, Shitalben R Patel, Minoli A Perera, Richard T Campbell, Rick A Kittles, Larisa H Cavallari. Pharmacogenomics 2012
47
9

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
Andrea H Ramirez, Yaping Shi, Jonathan S Schildcrout, Jessica T Delaney, Hua Xu, Matthew T Oetjens, Rebecca L Zuvich, Melissa A Basford, Erica Bowton, Min Jiang,[...]. Pharmacogenomics 2012
71
9

Pharmacogenomics of warfarin in populations of African descent.
Guilherme Suarez-Kurtz, Mariana R Botton. Br J Clin Pharmacol 2013
29
13

Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.
S E Kimmel, J Christie, C Kealey, Z Chen, M Price, C F Thorn, C M Brensinger, C W Newcomb, A S Whitehead. Pharmacogenomics J 2008
70
9

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Alan R Shuldiner, Jeffrey R O'Connell, Kevin P Bliden, Amish Gandhi, Kathleen Ryan, Richard B Horenstein, Coleen M Damcott, Ruth Pakyz, Udaya S Tantry, Quince Gibson,[...]. JAMA 2009
9

Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Mary J Emond, Tin Louie, Julia Emerson, Wei Zhao, Rasika A Mathias, Michael R Knowles, Fred A Wright, Mark J Rieder, Holly K Tabor, Deborah A Nickerson,[...]. Nat Genet 2012
161
9

PLINK: a tool set for whole-genome association and population-based linkage analyses.
Shaun Purcell, Benjamin Neale, Kathe Todd-Brown, Lori Thomas, Manuel A R Ferreira, David Bender, Julian Maller, Pamela Sklar, Paul I W de Bakker, Mark J Daly,[...]. Am J Hum Genet 2007
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.